You are here

Pediatric Therapy for Methylmalonic Acidemia Gets OD Designation

Rare, Life-threatening Disease Has No Approved Treatment

LogicBio Therapeutics, Inc. has received an orphan drug designation from the FDA for LB-001, a recombinant adeno-associated viral vector with human methylmalonyl-COA mutase (MUT) gene, for the treatment of methylmalonic acidemia (MMA).

LB-001, an investigational pediatric genome editing therapy, is based on LogicBio’s GeneRide™ technology, which enables site-specific integration and lifelong expression of therapeutic transgenes without using exogenous promoters or nucleases. LB-001 is designed to incorporate a functioning version of the faulty MUT gene into the patient’s genome.

LogicBio demonstrated preclinical proof-of-concept of GeneRide in multiple animal models of the disease, improving survival and reversing disease pathology. In preclinical MMA models, when GeneRide inserted a transgene into cells, they demonstrated a selective survival advantage over cells not expressing the transgene.

The rare methylmalonic acidemia, an autosomal recessive disease, begins in early childhood. It prevents the proper processing of certain fats and proteins, which results in a toxic buildup of metabolites that can cause life-threatening decompensations in infants and children. This can lead to significant morbidity and mortality, including infections, neurodevelopmental disabilities, and chronic kidney disease.

MMA is inherited in an autosomal recessive pattern; both copies of the MMUT, MMAA, MMAB, MMADHC, or MCEE gene in each cell have mutations. Typically, parents of affected individuals carry one copy of the mutated gene but they do not show signs and symptoms of the condition.

Source: LogicBio Therapeutics, Inc., April 29, 2019; National Library of Medicine, April 30, 2019.


Recent Headlines

Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients
Statistically Significant Improvement in Excessive Daytime Sleepiness
Researcher Made Himself Guinea Pig to Test the Drug
Treatment Shorter, Less Complicated Than Typical Regimen
Zip Device Faster to Apply, Minimizes Scarring